Skip to main content
SpringerLink
Log in

Forum

  • Update
  • Published:
Pharmaceutical Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

References

  1. European Medicines Agency. Announcement of European Medicines Agency priorities for adverse drug reaction research: 5th Call FP7. 2010 Jul 1 [online]. Available from URL: http://www.ema.europa.eu [Accessed 2010 Jul 5]

    Google Scholar 

  2. European Medicines Agency. European Medicines Agency 2011 priorities for drug safety research: insulin/insulin analogues and cancer. 2010 Jul 1 [online]. Available from URL: http://www.ema.europa.eu [Accessed 2010 Jul 5]

    Google Scholar 

  3. European Medicines Agency. European Medicines Agency 2011 priorities for drug safety research: anti diabetic drugs: cardio/cerebrovascular adverse effect and pancreatitis/pancreatic cancer. 2010 Jul 1 [online]. Available from URL: http://www.ema.europa.eu [Accessed 2010 Jul 5]

    Google Scholar 

  4. European Medicines Agency. European Medicines Agency 2011 priorities for drug safety research: epoetins and tumour progression, shortened survival, mortality and thromboembolic events. 2010 Jul 1 [online]. Available from URL: http://www.ema.europa.eu [Accessed 2010 Jul 5]

    Google Scholar 

  5. European Medicines Agency. European Medicines Agency 2011 priorities for drug safety research: asthma treatments (long and short-acting beta agonists and anticholinergics). Risk of myocardial ischaemia and long term safety, especially in children. 2010 Jul 1 [online]. Available from URL: http://www.ema.europa.eu [Accessed 2010 Jul 5]

    Google Scholar 

  6. European Medicines Agency. European Medicines Agency 2011 priorities for drug safety research: gadolinium-containing contrast agents and nephrogenic systemic fibrosis: long-term consequences of retention in human skin and bone. 2010 Jul 1 [online]. Available from URL: http://www.ema.europa.eu [Accessed 2010 Jul 5]

    Google Scholar 

Reference

  • Food and Drug Administration. FDA and NIH launch electronic safety reporting portal [media release]. 2010 May 24 [online]. Available from URL: http://www.fda.com [Accessed 2010 May 25]

    Google Scholar 

References

  1. Postel-Vinay S, Gomez-Roca CA, Molife LR, et al. Phase I trials of novel molecularly targeted therapies: should we pay more attention to toxicities occurring after cycle 1? [abstract no. 2515]. 46th Annual Meeting of the American Society of Clinical Oncology; 2010 Jun 4–8; Chicago (IL) [online]. Available from URL: http://www.asco.org [Accessed 2010 Jul 9]

    Google Scholar 

  2. Alam SM, Fehrmann RS, Olmos D, et al. Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single-center experience [abstract no. 2519]. 46th Annual Meeting of the American Society of Clinical Oncology; 2010 Jun 4–8; Chicago (IL) [online]. Available from URL: http://www.asco.org [Accessed 2010 Jul 9]

    Google Scholar 

  3. Iasonos A, Zohar S, O’Quigley J. Impact of miscoding dose-limiting toxicities in dose-escalation phase I studies [abstract no. e13007]. 46th Annual Meeting of the American Society of Clinical Oncology; 2010 Jun 4–8; Chicago (IL) [online]. Available from URL: http://www.asco.org [Accessed 2010 Jul 9]

    Google Scholar 

  4. Gomez-Roca CA, Baey C, Olmos D, et al. An international pooled analysis identifying predictive factors associated with toxicities in phase I trials (Delphi) [abstract no. 2517]. 46th Annual Meeting of the American Society of Clinical Oncology; 2010 Jun 4–8; Chicago (IL) [online]. Available from URL: http://www.asco.org [Accessed 2010 Jul 9]

    Google Scholar 

  5. Negrier S, Pérol D, Soria J, et al. Attempt to improve the safety of development studies with a new design for phase I combination trials of targeted therapies: the PARASOL trial [abstract no. TPS165]. 46th Annual Meeting of the American Society of Clinical Oncology; 2010 Jun 4–8; Chicago (IL) [online]. Available from URL: http://www.asco.org [Accessed 2010 Jul 9]

    Google Scholar 

Reference

  • ESMT Competition Analysis. Cutting drug prices can hamper development of new medicines, shows new study by ESMT Competition Analysis [media release]. 2010 Jul 1 [online]. Available from URL: http://www.esmt.org [Accessed 2010 Jul 5]

    Google Scholar 

References

  1. Alvarez Y, Hidalgo A, Maignen F, et al. Validation of statistical signal detection procedures in EudraVigilance post-authorization data: a retrospective evaluation of the potential for earlier signalling. Drug Saf 2010; 33 (6): 475–87

    Article  PubMed  Google Scholar 

  2. European Medicines Agency. EudraVigilance signal detection methods help detect drug safety issues earlier [media release]. 2010 May 25 [online]. Available from URL: http://www.emea.europa.eu [Accessed Jun 21]

    Google Scholar 

Reference

  • World Health Organization. New WHO guidance to improve use of medicines for children [media release]. 2010 Jun 18 [online]. Available from URL: http://www.who.int [Accessed Jun 21]

    Google Scholar 

References

  1. Food and Drug Administration. FDA Transparency Task Force unveils draft proposals on agency disclosure policies [media release]. 2010 May 19 [online]. Available from URL: http://www.fda.gov [Accessed 2010 May 21]

    Google Scholar 

  2. Asamoah AK, Sharfstein JM. Transparency at the Food and Drug Administration. N Engl J Med 2010; 362 (25): 2341–3

    Article  PubMed  CAS  Google Scholar 

Reference

  • Business Wire. First-of-its-kind study advises of potential for increased medication errors [media release]. 2010 May 26 [online]. Available from URL: http://www.businesswire.com [Accessed 2010 Jun 11]

    Google Scholar 

Reference

Reference

  • Wiatr C. Practical limitations to cost effectiveness research: major cuts to drug pricing in Europe unlikely. 2010 Jun 22 [online]. Available from URL: http://www.in-thought.com [Accessed Jun 25]

    Google Scholar 

Reference

  • Tuffs A. Future head of German NICE sets out ambitions for health care. BMJ 2010; 340: c3275

    Article  Google Scholar 

References

  1. Minister for Health and Children. Minister Harney publishes report on proposed model for the substitution of interchangeable (generic) medicines and reference pricing [media release]. 2010 Jun 17 [online]. Available from URL: http://www.dohc.ie [Accessed 2010 Jun 21]

    Google Scholar 

  2. Irish Pharmacy Union. Pharmacists welcome lower medicines prices through generic substitution [media release]. 2010 Jun 17 [online]. Available from URL: http://www.ipu.ie [Accessed 2010 Jun 21]

    Google Scholar 

  3. Irish Pharmaceutical Healthcare Association. IPHA statement on the report on a proposed model for reference pricing and generic substitution [media release]. 2010 Jun 17 [online]. Available from URL: http://www.ipha.ie [Accessed 2010 Jun 21]

    Google Scholar 

Reference

  • Mordin M, Lewis S, Gnanasakthy A, et al. Patient-reported outcomes in product development guidance [abstract no. PMC21]. 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; 2010 May 15–19; Atlanta (GA) [online]. Available from URL: http://www.ispor.org [Accessed 2010 Jun 21]

    Google Scholar 

References

  1. Mason A, Drummond M, Ramsey S, et al. Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric? J Clin Oncol 2010; 28 (20) 3234–8

    Article  PubMed  Google Scholar 

  2. Malin JL. Wrestling with the high price of cancer care: should we control costs by individuals’ ability to pay or society’s willingness to pay? J Clin Oncol 2010; 28 (20): 3212–4

    Article  PubMed  Google Scholar 

Reference

  • Taylor L. UK, Norway and Sweden have Europe’s lowest drug prices: report [online]. Available from URL: http://www.pharmatimes.com [Accessed 2010 Jun 18]

Reference

  • Carman KL, Maurer M, Mathews Yegian J, et al. Evidence that consumers are skeptical about evidence-based health care. Health Aff 2010; 29 (7): 1–7

    Article  Google Scholar 

References

  1. Rizzoli AJ. Is health outcomes research valuable to real decision makers? 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; 2010 May 15–19; Atlanta (GA) [online]. Available from URL: http://www.ispor.org [Accessed 2010 Jun 21]

    Google Scholar 

  2. Schaecher KL. The value of health outcomes research to managed care decision makers. 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; 2010 May 15–19; Atlanta (GA) [online]. Available from URL: http://www.ispor.org [Accessed 2010 Jun 21]

    Google Scholar 

  3. Watkins J. Is health outcomes research valuable to U.S. private payers? 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; 2010 May 15–19; Atlanta (GA) [online]. Available fromURL: http://www.ispor.org [Accessed 2010 Jun 21

    Google Scholar 

  4. Gardner HH. Is health outcomes research valuable to real decision makers? 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; 2010 May 15–19; Atlanta (GA) [online]. Available from URL: http://www.ispor.org [Accessed 2010 Jun 21]

    Google Scholar 

Reference

  • Rhodin A, Stridsberg M, Gordh T. Opioid endocrinopathy: a clinical problem in patients with chronic pain and long-term oral opioid treatment. Clin J Pain 2010; 26 (5): 374–80

    Article  PubMed  Google Scholar 

References

  1. Klein NP, Fireman B, Yih WK, et al. Measles-Mumps-Rubella-Varicella combination vaccine and the risk of febrile seizures. Pediatrics 2010; 126 (1): E1–8

    Article  PubMed  Google Scholar 

  2. Kaiser Permanente. Combination MMRV vaccine associated with twofold risk of febrile seizures compared with separate MMR & varicella vaccines [media release]. 2010 Jun 29 [online]. Available from URL: http://www.kaiserpermanente.org [Accessed 2010 Jul 1]

    Google Scholar 

References

  1. European Medicines Agency. European Medicines Agency starts review of rosiglitazone-containing medicines [media release]. 2010 Jul 9 [online]. Available from URL: http://www.ema.europa.eu [Accessed 2010 Jul 12]

    Google Scholar 

  2. Health Canada. Status of rosiglitazone drugs in Canada (Avandia®, Avandamet®, and Avandaryl™). 2010 Jul 8 [online]. Available from URL: http://www.hc-sc.gc.ca [Accessed 2010 Jul 12]

    Google Scholar 

References

  1. Sipahi I, Debanne SM, Rowland DY, et al. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 2010; 11 (7): 605–6

    Article  Google Scholar 

  2. Nissen SE. Angiotensin-receptor blockers and cancer: urgent regulatory review needed. Lancet Oncol 2010; 11 (7): 627–36

    Article  Google Scholar 

Reference

Reference

  • Rishi MA, Shetty M, Wolff A, et al. Atypical antipsychotic medications are independently associated with severe obstructive sleep apnea. Clin Neuropharmacol 2010; 33 (3): 109–13

    Article  PubMed  Google Scholar 

Reference

  • Sokolove J, Strand V, Greenberg JD, et al. Risk of elevated liver enzymes associated with TNF inhibitor utilisation inpatients with rheumatoid arthritis. Ann Rheum Dis: 6 May 2010 [online]. Available from URL: http://dx.doi.org/10.1136/ard.2009.112136 [Accessed 2010 May 7]

    Google Scholar 

Reference

  • Misra M, Le Clair M, Mendes N, et al. Use of SSRIs may impact bone density in adolescents and young women with anorexia nervosa [abstract no. OR08-3]. 92nd Annual Meeting & Expo of the Endocrine Society; 2010 Jun 19–22; San Diego (CA) [online]. Available from URL: http://www.endo-society.org [Accessed 2010 Jul 14]

    Google Scholar 

Reference

  • Canevini MP, De Sarro G, Galimberti CA, et al. Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy. Epilepsia 2010; 51 (5): 797–804

    Article  PubMed  CAS  Google Scholar 

Reference

  • Thompson AJ, Fellay J, Patel K, et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology. Epub 2010 Jun 11

    Google Scholar 

References

  1. Patel P, Roberts S, Sparrowhawk K, et al. Evaluating comparative effectiveness research for oncology in the US: an analysis based on lessons from health technology assessments in Europe [abstract no. PCN142]. 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; 2010 May 15–19; Atlanta (GA) [online]. Available from URL: http://www.ispor.org [Accessed 2010 Jun 21]

    Google Scholar 

  2. Bending MW, Hutton J, McGrath C. Comparative effectiveness versus cost effectiveness: a comparison of the French and Scottish approaches to single technology assessment (STA) [abstract no. HT1]. 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; 2010 May 15–19; Atlanta (GA) [online]. Available from URL: http://www.ispor.org [Accessed 2010 Jun 21]

    Google Scholar 

  3. Leung MY, West ND, Halpern M, et al. Evidence used during pharmaceutical technology assessment [abstract no. PHP88]. 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; 2010 May 15–19; Atlanta (GA) [online]. Available from URL: http://www.ispor.org [Accessed 2010 Jun 21]

    Google Scholar 

  4. O’Day K, Reeder G, Bramley T, et al. Economic models: managed care decision maker’s perceptions and use [abstract no. PHP36 plus poster]. 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; 2010 May 15–19; Atlanta (GA) [online]. Available from URL: http://www.ispor.org [Accessed 2010 Jun 21]

    Google Scholar 

  5. Zema C, Rybowski L. The use of comparative effectiveness information by formulary decision-makers [abstract no. PHP37]. 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; 2010 May 15–19; Atlanta (GA) [online]. Available from URL: http://www.ispor.org [Accessed 2010 Jun 21]

    Google Scholar 

  6. Seidenfeld JD, Sonnad S, Gruman J. More effectively engaging consumers in comparative effectiveness research [abstract no. PHP1 plus poster]. 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; 2010 May 15–19; Atlanta (GA) [online]. Available from URL: http://www.ispor.org [Accessed 2010 Jun 21]

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Forum. Pharm Med 24, 239–253 (2010). https://doi.org/10.1007/BF03256822

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03256822

Search

Navigation